about
Structure of SF-1 Bound by Different Phospholipids: Evidence for Regulatory LigandsSmall Molecule Agonists of the Orphan Nuclear Receptors Steroidogenic Factor-1 (SF-1, NR5A1) and Liver Receptor Homologue-1 (LRH-1, NR5A2)Ligand structural motifs can decouple glucocorticoid receptor transcriptional activation from target promoter occupancyRegulation of C. elegans fat uptake and storage by acyl-CoA synthase-3 is dependent on NR5A family nuclear hormone receptor nhr-25.The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1.Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket.Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes.Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolismDisentangling biological signaling networks by dynamic coupling of signaling lipids to modifying enzymes.Phospholipid regulation of the nuclear receptor superfamily.Nuclear phosphoinositide regulation of chromatin.Direct modification and activation of a nuclear receptor-PIP₂ complex by the inositol lipid kinase IPMK.Applying innovative educational principles when classes grow and resources are limited: Biochemistry experiences at Muhimbili University of Allied Health Sciences.Crystallographic and kinetic analyses of human IPMK reveal disordered domains modulate ATP binding and kinase activityStabilization of the unliganded glucocorticoid receptor by TSG101Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease
P50
Q27652795-6BB92594-3571-4C5D-99DB-69EB01E8B858Q27667247-D25D2573-2C41-4CCF-80F6-B795FCA29D95Q28568722-D5AA2103-4990-4885-AD9C-1E5FE334EEDEQ34356028-386010CA-8C94-4080-B201-7502F22D39E4Q34408784-0BB824D7-035D-4DE7-9B0E-CE86F2C20589Q36296659-0B3902C0-BEA4-4A69-8F5D-D989CE3460E2Q37235520-CEA85E9F-7CB6-41F8-B1E1-06D96B67D6F2Q37375092-B2D4D442-BC23-4CA4-9AE0-5F6774E93203Q37737248-97217DDD-B341-4414-934F-B446501E2CCAQ38157461-B594F6BD-E960-4E9B-B243-166DC8FEB0CDQ39006591-8A7DA833-77D5-485E-A091-3B9A8242F0ECQ39159757-4E860508-D114-4E17-A7A9-E737BEFB1036Q42077086-67880263-2C80-4E29-8AC9-2821A925A783Q46836159-76336A07-2530-4343-B7F6-59CC9545438BQ59329139-C292401B-E819-4259-9588-18B3CD738403Q81289289-2640D253-9ED9-4598-9336-8C791D73D7DDQ91368710-E9436E35-BD78-47F2-A27D-40CF3E72A27D
P50
description
medical researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raymond D Blind
@ast
Raymond D Blind
@es
Raymond D Blind
@nl
Raymond D. Blind
@en
type
label
Raymond D Blind
@ast
Raymond D Blind
@es
Raymond D Blind
@nl
Raymond D. Blind
@en
prefLabel
Raymond D Blind
@ast
Raymond D Blind
@es
Raymond D Blind
@nl
Raymond D. Blind
@en
P106
P21
P31
P496
0000-0002-1358-6309